Quick Answer
NEOGENOMICS INC reported R&D Expense of $37.08 million for fiscal year 2025.
NEOGENOMICS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $37.08M | +19.0% |
| 2024 | $31.16M | +14.1% |
| 2023 | $27.31M | -9.9% |
| 2022 | $30.33M | +38.6% |
| 2021 | $21.87M | +165.8% |
| 2020 | $8.23M | -3.0% |
| 2019 | $8.49M | +182.8% |
| 2018 | $3.00M | -17.5% |
| 2017 | $3.64M | -21.8% |
| 2016 | $4.65M | +10.7% |
| 2015 | $4.20M | +56.1% |
| 2014 | $2.69M | +10.2% |
| 2013 | $2.44M | +7.0% |
| 2012 | $2.28M | +320.1% |
| 2011 | $543.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.69M | +13.1% | -3.6% |
| June 30, 2025 | $9.02M | +14.4% | -11.4% |
| March 31, 2025 | $10.18M | +33.6% | +32.5% |
| September 30, 2024 | $7.68M | +45.4% | -2.6% |
| June 30, 2024 | $7.89M | +5.1% | +3.5% |
| March 31, 2024 | $7.62M | +3.0% | +44.2% |
| September 30, 2023 | $5.29M | -27.7% | -29.6% |
| June 30, 2023 | $7.50M | -13.0% | +1.4% |
- NEOGENOMICS INC showed an increase of +19.0% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, NEOGENOMICS INC’s r&d expense has grown by 6728.2% (from $543.0 thousand to $37.08 million).
- The most recent figure is from NEOGENOMICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: